Argento Elena, Goldenberg Shira, Deering Kathleen, Lavalley Jennifer, Braschel Melissa, Bingham Brittany, Shannon Kate
Department of Medicine, University of British Columbia, 5804 Fairview Avenue, Vancouver V6T 1Z3 BC, Canada.
Centre for Gender & Sexual Health Equity, 1081 Burrard, Vancouver V6Z 1Y6, BC, Canada.
Drug Alcohol Depend Rep. 2022 Mar 16;3:100044. doi: 10.1016/j.dadr.2022.100044. eCollection 2022 Jun.
Psychedelic-assisted therapies are receiving mounting attention for their therapeutic potential. However, little is known about interest among women who experience elevated risk of mental health and substance use disorders. This study examined interest in receiving psychedelic-assisted therapy and socio-structural factors associated with interest among marginalized women.
Data (2016-2017) were drawn from two community-based, prospective open cohorts of >1000 marginalized women in Metro Vancouver, Canada. Bivariate and multivariable logistic regression examined associations with interest in receiving psychedelic-assisted therapy. Among women who used psychedelics, additional data were collected to describe ratings of personal meaningfulness, sense of wellbeing, and spiritual significance.
Of 486 eligible participants (aged 20-67 years), 43% ( = 211) were interested in receiving psychedelic-assisted therapy. Over half identified as Indigenous (First Nations, Métis or Inuit). Factors independently associated with interest in psychedelic-assisted therapy in multivariable analysis included: daily crystal methamphetamine use in the last six months (Adjusted Odds Ratio [AOR] 3.02; 95%Confidence Interval (CI) 1.37-6.65), lifetime mental health conditions (depression, anxiety, post-traumatic stress disorder) (AOR 2.13; 95%CI 1.27-3.59), childhood abuse (AOR 1.99; 95%CI 1.02-3.88), lifetime psychedelic use (AOR 1.97; 95%CI 1.14-3.38), and younger age (AOR 0.97 per year older; 95%CI 0.95-0.99).
Several mental health and substance use-related variables that have been demonstrated to be amenable to psychedelic-assisted therapy were associated with interest in receiving psychedelic-assisted therapy among women in this setting. As access to psychedelic-assisted therapies continues to expand, any future approaches to extend psychedelic medicine to marginalized women should integrate trauma-informed care and broader socio-structural supports.
迷幻剂辅助疗法因其治疗潜力而受到越来越多的关注。然而,对于心理健康和物质使用障碍风险较高的女性的兴趣了解甚少。本研究调查了接受迷幻剂辅助疗法的兴趣以及与边缘化女性兴趣相关的社会结构因素。
数据(2016 - 2017年)取自加拿大温哥华都会区两个基于社区的、超过1000名边缘化女性的前瞻性开放队列。双变量和多变量逻辑回归分析了与接受迷幻剂辅助疗法兴趣的关联。在使用过迷幻剂的女性中,收集了更多数据以描述个人意义、幸福感和精神意义的评分。
在486名符合条件的参与者(年龄20 - 67岁)中,43%(n = 211)有兴趣接受迷幻剂辅助疗法。超过一半的人认定为原住民(第一民族、梅蒂斯或因纽特人)。多变量分析中与迷幻剂辅助疗法兴趣独立相关的因素包括:过去六个月每日使用冰毒(调整后的优势比[AOR] 3.02;95%置信区间[CI] 1.37 - 6.65)、终生心理健康状况(抑郁症、焦虑症、创伤后应激障碍)(AOR 2.13;95%CI 1.27 - 3.59)、童年期受虐(AOR 1.99;95%CI 1.02 - 3.88)、终生使用迷幻剂(AOR 1.97;95%CI 1.14 - 3.38)以及年龄较小(每年年长一岁AOR为0.97;95%CI 0.95 - 0.99)。
在这种情况下,一些已被证明适合迷幻剂辅助疗法的心理健康和物质使用相关变量与女性接受迷幻剂辅助疗法的兴趣相关。随着迷幻剂辅助疗法的可及性不断扩大,未来将迷幻剂药物推广到边缘化女性的任何方法都应整合创伤知情护理和更广泛的社会结构支持。